FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of immunology, medicine and biotechnology. Claimed are versions of anti-EPHA2 antibodies. Claimed antibodies are bound with polypeptide, consisting of amino acids 426-534 in SEQ ID NO:8. Also described are hybridomes, which produce such antibodies, and pharmaceutical compositions and methods of application of said antibodies and compositions.
EFFECT: invention can be used in medicine.
74 cl, 14 dwg, 14 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY AGAINST GPR20 AND ANTIBODY AGAINST GPR20-DRUG CONJUGATES | 2018 |
|
RU2772804C2 |
| ANTI-B7-H3-ANTIBODY | 2012 |
|
RU2668170C2 |
| ANTI-GARP ANTIBODY | 2016 |
|
RU2769379C2 |
| ANTI-ROBO4 ANTIBODY | 2013 |
|
RU2682451C2 |
| ANTIBODY SELECTIVE TO APOPTOSIS INDUCING LIGAND RECEPTOR ASSOCIATED WITH TUMOR NECROSIS FACTOR, AND USES THEREOF | 2001 |
|
RU2298013C2 |
| DRUGS FOR CANCER TREATMENT AND/OR PREVENTION | 2011 |
|
RU2624029C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND PREVENTING MALIGNANT GROWTHS | 2009 |
|
RU2498819C2 |
| ANTI-TUMOUR ANTIGEN ANTIBODY AND METHODS OF APPLICATION | 2011 |
|
RU2598711C2 |
| ANTI-CD3-ANTIBODY AND MOLECULE CONTAINING THIS ANTIBODY | 2017 |
|
RU2790326C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND PREVENTING CANCER | 2009 |
|
RU2533460C2 |
